Helicos Seeks to Raise $6.4M in Direct Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Helicos BioSciences said after the close of the market yesterday that it has priced a registered direct offering of 6.4 million units at $1 per unit, which would provide the firm with $6.4 million in gross proceeds.

Each unit in the offering consists of one share of Helicos common stock and a warrant to buy .65 of a share of common stock. The warrants are exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share.

Helicos expects to close the offering on or around Dec. 21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.